Treatment outcomes of extended-field radiation therapy and the effect of concurrent @entity5 with para-aortic lymph node XXXX .

@entity1 @entity137 @entity5 @entity2622 @entity344 @entity3 @entity1349
PURPOSE: To review the clinical outcomes of extended-field radiation therapy (EFRT) and to analyze prognostic factors significant for survival in @entity1 receiving EFRT for uterine @entity2622 with para-aortic node (PAN) @entity3 . @entity1 AND METHODS: We retrospectively reviewed 90 @entity1 with @entity5 and PAN @entity3 between 1987 and 2012. Median age was 50 (range, 24-77). @entity1 received median 70.2 Gy (range, 56-93) to point A and median 50.4 Gy (range, 45-60.4) to PAN over median 69 elapsed days (range, 43-182). Forty-six @entity1 (51.1%) received concurrent chemotherapy. Survival was calculated using the Kaplan-Meier method. We analyzed prognostic factors for @entity1349 ( @entity1349 ) and progression-free survival (PFS) using a Cox regression method. RESULTS: The median follow-up period for surviving @entity1 was 55 months (range, 3-252). Seventy @entity1 (77.8%) had complete remission. Forty-six @entity1 experienced treatment failure as follows: 11 @entity1 (12.2%) as local recurrence, 19 (21%) as regional recurrence and 33 (36.7%) as distant @entity3 . The 5-yr @entity1349 and PFS were 62.6% and 43.9%, respectively. Treatment response was the only statistically independent prognostic factors for @entity1349 (p= 0.04) and PFS (p< 0.001) on multivariate analysis. Grade 3 or 4 hematologic @entity344 were observed in about 10% of @entity1 . CONCLUSIONS: Our institutional experiences showed that EFRT was an effective treatment for @entity5 @entity1 with PAN @entity3 . The addition of chemotherapy to EFRT seems to have uncertain survival benefit with higher hematologic @entity137 .
